Proteomics International Laboratories Ltd 2024 AR2
The report outlines Proteomics International Laboratories Ltd's operational and financial highlights for the fiscal year ended June 30, 2024. The company advanced its predictive diagnostic tests, including PromarkerD, PromarkerEndo, and PromarkerEso, and secured a US Medicare reimbursement price of US$390.75 for PromarkerD. Financially, the company completed a successful A$6.5 million institutional placement to fund further commercialization and pipeline development. On the ESG front, the company maintained gender diversity with 61% female staff overall and 67% in senior management, while continuing strategic scientific collaborations.
Company: Proteomics International Laboratories Ltd
Sector: Professional & technical services
Country: Australia
Year: 2024
Type: AR2
Pages: 47
Back to company
Proteomics International Laboratories Ltd
Annual Report
The report outlines Proteomics International Laboratories Ltd's operational and financial highlights for the fiscal year ended June 30, 2024. The company advanced its predictive diagnostic tests, including PromarkerD, PromarkerEndo, and PromarkerEso, and secured a US Medicare reimbursement price of US$390.75 for PromarkerD. Financially, the company completed a successful A$6.5 million institutional placement to fund further commercialization and pipeline development. On the ESG front, the company maintained gender diversity with 61% female staff overall and 67% in senior management, while continuing strategic scientific collaborations.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jul 1, 2023 - Jun 30, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management